Siemens Healthineers Opens Innovation Center in Erlangen

Siemens HealthineersSiemens Healthineers has opened its new Innovation Center in Erlangen, Germany, in the heart of the regional medical technology research area known as Medical Valley. The focus is on open innovation by collaborating with external partner companies, start-ups and academic and clinical institutions to improve healthcare worldwide. The innovation center complements an existing ecosystem of centers in Shanghai, China, and Bengaluru, India. The underpinning idea is to create an infrastructure to strengthen innovation across the region, promote open collaboration in research, development and production, and enable customer- and market-oriented development.

"With our new Innovation Center, we are highlighting our commitment to the Erlangen and Forchheim locations and continuing to consistently implement our strategy of an open innovation culture," said Peter Schardt, Chief Technology Officer (CTO) of Siemens Healthineers. "The goal is to jointly focus on new technologies and value-added processes that have the potential to disrupt the healthcare system for the benefit of patients. By promoting open collaborations and projects, Siemens Healthineers and its customers will enable more people around the world to access high-quality medical care - from precise diagnosis to the right therapy."

Among other things, the company’s ASOR community has a co-working space in the new premises to further advance research and development for extended reality applications with internal and external partner companies, and to make digital content more tangible. Specifically, the aim is to test and develop prototypes and to virtually simulate medical technology solutions and applications, for example for training.

The Innovation Center is also home to partnerships such as the digital health innovation platform d.hip, an alliance of industry, university medicine and research organizations which aims to advance the digitization of the healthcare system.

In fiscal 2022 Siemens Healthineers invested around €1.8 billion in research and development and holds around 23,000 technical property rights, including around 15,000 granted patents.

About Siemens Healthineers

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers breakthroughs in healthcare. For everyone. Everywhere. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers and its regional companies are continuously developing their product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company's foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers' ability to provide high-quality, efficient care. In fiscal 2022, which ended on September 30, 2022, Siemens Healthineers, which has approximately 69,500 employees worldwide, generated revenue of around €21.7 billion and adjusted EBIT of almost €3.7 billion.

Most Popular Now

Stepping Hill Hospital Announced as SPAR…

Stepping Hill Hospital, part of Stockport NHS Foundation Trust, has replaced its bedside units with state-of-the art devices running a full range of information, engagement, communications and productivity apps, to...

DMEA 2025: Digital Health Worldwide in B…

8 - 10 April 2025, Berlin, Germany. From the AI Act, to the potential of the European Health Data Space, to the power of patient data in Scandinavia - DMEA 2025...

Is AI in Medicine Playing Fair?

As artificial intelligence (AI) rapidly integrates into health care, a new study by researchers at the Icahn School of Medicine at Mount Sinai reveals that all generative AI models may...

New System for the Early Detection of Au…

A team from the Human-Tech Institute-Universitat Politècnica de València has developed a new system for the early detection of Autism Spectrum Disorder (ASD) using virtual reality and artificial intelligence. The...

Generative AI's Diagnostic Capabili…

The use of generative AI for diagnostics has attracted attention in the medical field and many research papers have been published on this topic. However, because the evaluation criteria were...

Diagnoses and Treatment Recommendations …

A new study led by Prof. Dan Zeltzer, a digital health expert from the Berglas School of Economics at Tel Aviv University, compared the quality of diagnostic and treatment recommendations...

AI Tool can Track Effectiveness of Multi…

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by UCL researchers. AI uses...

Surrey and Sussex Healthcare NHS Trust g…

Surrey and Sussex Healthcare NHS Trust has marked an important milestone in connecting busy radiologists across large parts of South East England, following the successful go live of Sectra's enterprise...

Dr Jason Broch Joins the Highland Market…

The Highland Marketing advisory board has welcomed a new member - Dr Jason Broch, a GP and director with a strong track record in the NHS and IT-enabled transformation. Dr Broch...

DMEA 2025 Ends with Record Attendance an…

8 - 10 April 2025, Berlin, Germany. DMEA 2025 came to a successful close with record attendance and an impressive program. 20,500 participants attended Europe's leading digital health event over the...

AI-Driven Smart Devices to Transform Hea…

AI-powered, internet-connected medical devices have the potential to revolutionise healthcare by enabling early disease detection, real-time patient monitoring, and personalised treatments, a new study suggests. They are already saving lives...

Multi-Resistance in Bacteria Predicted b…

An AI model trained on large amounts of genetic data can predict whether bacteria will become antibiotic-resistant. The new study shows that antibiotic resistance is more easily transmitted between genetically...